Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma
Brief Summary: This is an international multi-center prospective, double randomized, open, controlled phase III study with a phase II entrance phase to compare the therapeutic efficacy of thalidomide plus dexamethasone to conventional melphalan plus prednisone in newly diagnosed myeloma patients.


Options:
A: Arm Label: Bortezomib and Dexamethasone (VD); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Drug: Dexamethasone | Arm Label: Bortezomib, Thalidomide, and Dexamethasone (VTD); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Drug: Dexamethasone, Drug: Thalidomide | Arm Label: Bortezomib, Melphalan and Prednisone (VMP); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Drug: Melphalan, Drug: Prednisone | Intervention Type: DRUG; Name: Bortezomib; Assigned to Arm(s): Bortezomib and Dexamethasone (VD), Bortezomib, Melphalan and Prednisone (VMP), Bortezomib, Thalidomide, and Dexamethasone (VTD) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Bortezomib and Dexamethasone (VD), Bortezomib, Thalidomide, and Dexamethasone (VTD) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Bortezomib, Melphalan and Prednisone (VMP) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Bortezomib, Melphalan and Prednisone (VMP) | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Bortezomib, Thalidomide, and Dexamethasone (VTD)
B: Arm Label: Lenalidomide / Dexamethasone until disease progression; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide and low-dose dexamethasone | Arm Label: Lenalidomide / Dexamethasone for 18 cycles; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles | Arm Label: Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan, Prednisone and Thalidomide | Intervention Type: DRUG; Name: Lenalidomide and low-dose dexamethasone; Assigned to Arm(s): Lenalidomide / Dexamethasone until disease progression | Intervention Type: DRUG; Name: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles; Assigned to Arm(s): Lenalidomide / Dexamethasone for 18 cycles | Intervention Type: DRUG; Name: Melphalan, Prednisone and Thalidomide; Assigned to Arm(s): Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles
C: Intervention Type: DRUG; Name: Thalidomide/Dexamethasone vs Melphalan/Prednisone; Assigned to Arm(s): N/A
D: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR

Answer: C